Sage Journals: Discover world-class research

Abstract

Background:

¹⁷⁷LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting treatment intervals utilising early response biomarkers may improve patient outcomes.

Objective:

This study evaluated progression-free survival (PFS) and overall survival (OS) based on treatment interval adjustment utilising ¹⁷⁷LuPSMA 24-h SPECT/CT (¹⁷⁷Lu-SPECT) and early prostate-specific antigen (PSA) response.

Design:

Retrospective analysis of a clinical ¹⁷⁷Lu-PSMA-I&T treatment programme.

Methods:

In all, 125 men were treated with 6-weekly ¹⁷⁷LuPSMA-I&T [median 3 cycles, interquartile range (IQR): 2–4], median dose 8.0 GBq [95% confidence interval (CI): 7.5–8.0]. Imaging screening involved ⁶⁸GaPSMA-11 PET/diagnostic CT. ¹⁷⁷Lu-SPECT/diagnostic CT was acquired following each therapy, and clinical assessments 3-weekly. Following dose 2 (week 6), a composite PSA and ¹⁷⁷Lu-SPECT/CT imaging response [partial response (PR), stable disease (SD), and progressive disease (PD)] determined ongoing management. Response group (RG) 1 (marked reduction in PSA/imaging PR) break in treatment until subsequent PSA rise, then re-treatment. RG 2 (stable or reduced PSA and/or imaging SD) 6-weekly treatments until six doses, or no longer clinically benefitting. RG 3 (rise in PSA and/or imaging PD) recommended for an alternative treatment.

Results:

Overall PSA50% response rate (PSARR) was 60% (75/125), median PSA-PFS 6.1 months (95%CI: 5.5–6.7), and median OS 16.8 months (95%CI: 13.5–20.1). 35% (41/116) were classified as RG 1, 34% (39/116) RG 2, and 31% (36/116) RG 3. PSARRs by RG were 95% (38/41), 74% (29/39), and 8% (3/36); median PSA-PFS rates were 12.1 months (95%CI: 9.3–17.4), 6.1 months (95%CI: 5.8–9.0), and 2.6 months (95%CI: 1.6–3.1); and OS rates were 19.2 months (95%CI: 16.8–20.7), 13.2 months (95%CI: 12.0–18.8), and 11.2 months (95%CI: 8.7–15.6) for RG 1, 2, and 3, respectively. The median months of ‘treatment holiday’ for RG 1 was 6.1 months (IQR: 3.4–8.7). Nine men had received prior ¹⁷⁷LuPSMA-617 and were retreated with ¹⁷⁷LuPSMA-I&T, with a PSARR of 56% on re-treatment.

Conclusion:

Personalising dosing regimens using early response biomarkers with ¹⁷⁷LuPSMA has the potential to achieve similar treatment responses to continuous dosing while allowing treatment breaks or intensification. Further evaluation of early response biomarker-guided treatment regimens in prospective trials is warranted.

Plain Language Summary

Lutetium-PSMA therapy is a new therapy for metastatic prostate cancer that is well tolerated and effective. However, not all men respond equally, with some responding very well and others progressing early. Personalising treatments require tools that can accurately measure treatment responses, preferably early in the treatment course, so adjustments to treatment can be made. Lutetium-PSMA can measure tumour sites after each therapy by taking whole body 3D images at 24 h using a small radiation wave from the treatment itself. This is called a SPECT scan. Previous work has shown that both prostate-specific antigen (PSA) response and changes in tumour volume on a SPECT scan can predict how patients will respond to treatment as early as dose 2. This study demonstrates that stratifying how men are treated based on the results of the 6-week SPECT scan and PSA response potentially allows a third of men to have break in treatment and that these men have both longer time to disease progression and OS. Men with an increase in tumour volume and increase in PSA early in treatment (6 weeks) had shorter time to disease progression and OS. Men with early biomarker disease progression were offered alternative treatments early in an attempt to allow the opportunity to allow a more effective potential therapy, if one was available. The study is an analysis of a clinical programme, and was not a prospective trial. As such, there are potential biases that could influence results. Hence, while the study is encouraging for the use of early response biomarkers to guide better treatment decisions, this must be validated in a well-designed clinical trial.

Keywords

lutetium-PSMA metastatic prostate cancer SPECT response biomarker

Introduction

¹⁷⁷LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer (mCRPC) with trials predominantly adopting a standardised dose interval and course of treatment. The randomised TheraP trial allowed ‘treatment holidays’ in (7%) men with an exceptional response to ¹⁷⁷LuPSMA-617 based on ¹⁷⁷LuPSMA 24-h SPECT (¹⁷⁷Lu-SPECT) and prostate-specific antigen (PSA) response, while the VISION trial utilised continuous fixed-interval dosing until treatment was no longer clinically benefitting.^1,2 Adjusting treatment intervals utilising early response biomarkers may lead to improved patient outcomes. This study evaluates patient outcomes [progression-free survival (PFS) and overall survival (OS)] based on a response-guided treatment interval adjustment utilising both ¹⁷⁷Lu-SPECT/CT and PSA response biomarkers.

Materials and methods

Screening

Men with mCRPC, who had progressed on at least one line of androgen receptor signalling inhibition and either failed or were ineligible for prior taxane chemotherapy, were considered for treatment on a clinical treatment programme. All men underwent screening with ⁶⁸Ga-PSMA-11(PSMA) PET CT and diagnostic CT of the chest, abdomen, and pelvis. Men were eligible if they had a standardised uptake value (SUV) maximum > 15 on PSMA PET at ⩾1 site, and SUVmax > 10 at all measurable sites not impacted by partial voluming with no sites of soft tissue metastatic disease on diagnostic CT not meeting PSMA PET criteria. All patients required an eGFR > 30 mL/min, Hb > 70 g/L, platelets > 70 × 10⁹/L.

Production

PSMA-I&T precursor (ABX, Germany) in sodium acetate buffer was added to non-carrier added [¹⁷⁷Lu] LuCl₃ according to institutional production protocol. Radiochemical purity was determined using high-pressure liquid chromatography and thin-layer chromatography.

Imaging procedures and analysis

Screening ⁶⁸GaPSMA PET/CT and diagnostic CT were performed in all patients prior to consideration for treatment. All patients treated had ¹⁷⁷Lu-SPECT/CT (vertex to mid-thighs) acquired 24 h after each ¹⁷⁷LuPSMA-I&T injection using a Discovery 670 system and a Tandem NM/CT 870 DR (GE Healthcare, Milwaukee, WI, USA) with the following parameters: medium energy collimators, 3 bed positions, 60 projections over 360° with an acquisition time of 10 s per frame, 128 × 128 matrix and 4.42 × 4.42 mm² pixel size. An energy window centred on 208 keV ± 10% with a 165 keV ± 6.5% scatter window was used. A non-contrast low-dose CT scan was performed immediately after. In those studies that had all data available for quantitation, the SPECT projection images were reconstructed with an iterative Ordered Subset Estimation Maximum algorithm that used 4 iterations and 10 subsets using SPECTRA Quant™ (MIM Software, Inc, Cleveland, OH, USA). No pre- or post-reconstruction filters were applied. CT-based Attenuation Correction, Dual Energy Window Scatter Correction, collimator-based Resolution Recovery, and quantitative conversion to SUV were performed during the reconstruction. The conversion from counts to units of activity was calculated based on a cylinder phantom with known activity.³ SPECT quantification was undertaken in 77% (96/125), with the remainder missing key data require for reconstruction of analysable quantitative data (scatter windows).

Visual imaging analysis

All ¹⁷⁷Lu-SPECT/CT (vertex to mid-thigh) images were evaluated visually by an experienced nuclear medicine physician to assess for treatment response, as per clinical protocol. A significant response on imaging (between baseline and week-6 Lu-SPECT/CT) was defined as a marked reduction (>30%) in visual tumour volume at all sites of involved disease, no new sites of PSMA avid tumour deposits and no new sites of PSMA negative tumour deposits on diagnostic CT [imaging partial response (PR)]. Stable disease (SD) was classified as no visible marked change in tumour volume (>30%), no new sites of PSMA avid disease and no new sites of PSMA negative disease on diagnostic CT (imaging SD). Progressive disease (PD) was defined as visual increase in tumour volume (>30%) ± new sites of disease and/or the presence of new sites of PSMA-negative disease progression on diagnostic CT (imaging PD).

Quantitative imaging analysis

¹⁷⁷Lu-SPECT/CT was analysed semi-quantitatively by a nuclear medicine physician utilising MIM (LesionID™), MIM Software (Inc., Cleveland, OH, USA) software and a standardised semi-automated workflow to delineate regions of interest with a minimum SUV cut-off of 3 and lesion size ⩾ 0.2 mm.⁴ All lesions identified quantitatively were manually reviewed and physiologic activity was removed. Whole body quantitation derived total tumour volume (TTV), SUVmax, and SUVmean for PSMA-SPECT at baseline and week 6.⁵ 77% (96/125) men had analysable baseline and week-6 ¹⁷⁷Lu-SPECT/CT data. Quantitative analysis was derived retrospectively in patients with full analysable datasets, with the quantitative findings not included in clinical decisions. Clinical decisions regarding patient treatments were undertaken using visual assessment of the baseline and week-6 ¹⁷⁷Lu-SPECT/CT.

Study treatment

All men received a minimum two doses of ¹⁷⁷LuPSMA-I&T at 6-weekly intervals. A median 8 GBq [interquartile range (IQR): 8–8.5] was administered at each dose via slow intravenous injection. Blood was prospectively collected prior to each cycle and at 3-weekly intervals for biomarkers including haemoglobin, platelets, lactate dehydrogenase, alkaline phosphatase, albumin, and PSA. Following dose 2 of ¹⁷⁷LuPSMA (week 6), a composite of PSA response and imaging findings (imaging PR, SD, PD) were utilised to determine ongoing management. Response group (RG) 1: [marked reduction (50%) in PSA and imaging PR] break in treatment until subsequent PSA rise, then consider re-treatment. RG 2: [stable or reduced PSA (<50%) and/or imaging SD] ongoing 6-weekly treatments until six doses, or no longer clinically benefitting. RG 3: (rise in PSA and/or imaging PD) consider referral to an alternative treatment. All patients were followed for subsequent PSA progression and OS.

Statistical analyses

We measured PSA decline from baseline ⩾50% (PSA50) at any timepoint, PSA-PFS, and OS.^6,7 In patients with a treatment break PSA-PFS was defined from the date at which PSA rose, without PSA response to subsequent treatment. The Kaplan–Meier method was used to characterise time-to-event endpoints and estimate medians (presented with 95%CIs). Differences in TTV, SUVmax, SUVmean between the RGs were assessed using one-way analysis of variance. We correlated RG with time-to-event outcomes, using univariable Cox proportional hazards regression. p Values below 5% were considered significant but interpreted conservatively in view of the multiple tests.

Results

Patient characteristics

In all, 125 men underwent ¹⁷⁷LuPSMA-I&T therapy between May 2019 and April 2022. All men had mCRPC, 99% (124/125) had prior androgen receptor signalling inhibitors, and 70% (88/125) prior docetaxel. Mean age was 75 years (70–80) (Table 1). Patients received a median of three doses up to a maximum of 10 (IQR 2-4). 6% (9/125) had been previously treated on a clinical trial with ¹⁷⁷LuPSMA-617. Overall, 60% (75/125) had a PSA reduction >50% (PSARR). At the time of analysis, 42% (52/125) were deceased. In those assigned to an RG, 35% of men (41/116) were classified as RG 1, 34% (39/116) RG 2, and 31% (36/116) RG 3. Patients who had previously treated with ¹⁷⁷LuPSMA-617 on trial (9/125) were not assigned to a RG, with results reported separately.

Table 1.

Patient characteristics.

Characteristic	N = 125
Age (years)	75 (70–80)
Years since diagnosis	6 (3–9)
Prior systemic treatments
LHRH agonist/antagonist	100% (125/125)
Chemotherapy	70% (88/125)
Docetaxel	70% (88/125)
Cabazitaxel	35% (44/125)
Androgen receptor signalling inhibitor	99% (124/125)
PSA	76 (26.7–258.5)
LDH	242 (211–301)
Platelets	220 (177–271)
Haemoglobin	116 (103–127)
Sites of disease
Bone	97% (93/96)
Lymph nodes	47% (45/96)
Visceral	20% (19/96)

Numbers are presented as absolute counts (percentage) or median (interquartile range).

LDH, lactate dehydrogenase; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen.

Patient outcomes

In the overall study population, the median PSA-PFS was 6.1 months (95%CI: 5.4–6.7) and OS was 16.8 months (95%CI: 13.5–20.1). There was a significant difference in PSA-PFS between RGs, with RG 1 PSA-PFS [12.1 (9.3–17.4) months], RG 2 PSA-PFS [6.1 (5.8–9.0) months], and RG 3 PSA-PFS [2.6 (1.6–3.1) months; p < 0.0001). A significant difference was also noted in OS between RG 1 [19.2 (16.8–20.7) months], RG 2 [13.2 (12.0–18.8) months], and RG 3 [11.2 (8.7–15.6) months; p < 0.0005) (Figure 1). Similarly, PSA50%RR was also significantly different between RGs (p < 0.0001) (Table 2).

Figure 1.

Kaplan–Meier curve for (a) PSA-PFS in patients with marked reduction in PSA and imaging PR (blue) versus stable or reduced PSA and/or imaging SD (yellow) and rise in PSA and/or imaging PD (red) and (b) demonstrating OS in the same cohorts.

Table 2.

Patient outcomes.

	PSA 50% RR	Median PSA response	OS	PSA-PFS
Overall	60% (75/125)	51.8% (86.2 to −1.6)	16.8 (13.5–20.1)	6.1 (5.4–6.7)
RG 1	93% (38/41)	83% (−97 to −70)	19.2 (16.8–20.7)	12.1 (9.3–17.4)
RG 2	74% (29/39)	61% (89 to −35)	13.2 (12.0–18.8)	6.1 (5.8–9.0)
RG 3	8% (3/36)	−25% (−55 to −1)	11.2 (8.7–15.6)	2.6 (1.6–3.1)

Results presented as median (IQR).

IQR, interquartile range; PFS, progression-free survival; PSA, prostate-specific antigen; OS, overall survival; RS, response group.

Response group 1

Men in RG 1 received a median 3 (IQR: 2–4) doses of ¹⁷⁷LuPSMA-I&T. They had a 95% (38/41) PSA50%RR, and median reduction in PSA of 83% (IQR: −97 to −70). Median PSA50%RR at dose 2 was 49% (IQR: 69.1–23.3). In this RG, PSA-PFS was 12.1 months (95%CI: 9.3–17.4) and OS 19.2 months (95%CI: 16.8–20.7). All men in RG 1 had a treatment break due to significant treatment response, with a median 6.1 months (IQR: 3.4–8.7) of treatment ‘holiday’ prior to a subsequent rise in PSA and consideration for re-treatment. 51% (21/41) of these men had received prior chemotherapy. Median age of those not receiving chemotherapy in RG 1 was 82.5 years.

Response group 2

Men in RG 2 received a median 4 doses (IQR: 3–5) ¹⁷⁷LuPSMA-I&T. No patients had a treatment break. This RG had a PSA 50%RR of 74% (29/39), and a median reduction in PSA of 61% (IQR: 89–35). Median PSA 50%RR at dose 2 was 24% (IQR: 38 to −9). Median PSA-PFS 6.1 months (95%CI: 5.8–9.0) and OS 13.2 months (95%CI: 12.0–18.8). It was noted 82% (32/39) of these men had received prior chemotherapy.

Response group 3

Men in RG 3 received a median 3 (IQR: 2–3) doses ¹⁷⁷LuPSMA-I&T. The PSA50%RR was 8% (3/36). The three men with a PSA50%RR had new hepatic lesions (2/3) and perinephric soft tissue progression (1/3) on imaging. A PSA rise occurred in 92% (33/36) prior to C3. Median PSA-PFS was 2.6 months (95%CI: 1.6–3.1) and OS was 11.2 months (95%CI: 8.7–15.6). 78% (28/36) of these men had received prior chemotherapy.

Treatment following prior ¹⁷⁷LuPSMA-617

9/125 men had ¹⁷⁷LuPSMA-I-&T re-treatment after being treated in a clinical trial of ¹⁷⁷LuPSMA-617. All patients had six doses of ¹⁷⁷LuPSMA-617. These patients received a median of 2 (IQR: 2–3) additional doses of ¹⁷⁷LuPSMA-I&T. PSA50%RR following retreatment was 56% (5/9), with a median PSA-PFS of 4.9 months (95%CI: 1.5–8.3) and OS of 18.4 months (95%CI: 6.4–30).

Quantitative analysis of Lu-SPECT

Quantitative analysis of the baseline and week-6 ¹⁷⁷Lu-SPECT was possible in 77% (96/125) (Figure 2). Quantitative ¹⁷⁷Lu-SPECT characteristics of RGs 1–3 are detailed in Table 3. There was a significant difference in baseline ¹⁷⁷Lu-SPECT SUVmean between RGs, with the highest SUVmean in RG 1 (p < 0.01). The difference in Δ SUVmax between RGs was more significant with a large drop in SUVmax by week 6 in RG 1, and almost no change in Δ SUVmax in RG 3 (p < 0.01). A similar result was found with Δ SUVmean (Table 3).

Figure 2.

Imaging PR between baseline ¹⁷⁷Lu-SPECT (a) and week 6 (b). Imaging SD between baseline ¹⁷⁷Lu-SPECT (c) and week 6 (d). Imaging PD between baseline ¹⁷⁷Lu-SPECT (e) and week 6 (f).

Table 3.

Quantitative imaging subcohort: imaging results by RG.

Lu-SPECT	Overall	RG 1	RG 2	RG 3	Significance
BL TTV (mL)	526 (146–1223)	380 (124–980)	941 (265–1907)	374 (85–873)	<0.01
BL SUVmax	60 (37–88)	69 (47–117)	71 (46–100)	39 (19–67)	NS (0.06)
BL SUVmean	8.7 (7–12)	11 (8–14)	10 (7.8–14)	7 (5.2–8.5)	<0.01
Δ* TTV	−69 (−300 to 5.5)	−107(−260 to −14)	−150 (−574 to −8)	30 (−134 to 116)	NS (0.39)
Δ* SUVmax	−18 (−35 to −1.6)	−32 (−102 to −14)	−19 (−33 to 3)	−5 (−12 to 2)	<0.01
Δ* SUVmean	−1.5 (−3.5 to −0.1)	−3.3 (−6.8 to −1.8)	−1.6 (−2.7 to −0)	−0.5 (−1.4 to +0.2)	<0.01

Results presented as median (IQR).

Between BL and week-6 Lu-SPECT.

BL, baseline; IQR, interquartile range; RG, response group; SUV, standardised uptake value; TTV, total tumour volume.

Discussion

This study has found that early response biomarker-guided PSMA-targeted radionuclide therapy utilising a combination of PSA and ¹⁷⁷Lu-SPECT/CT response at week 6 may effectively stratify responders and limited/ non-responders. This enabled significant treatment de-intensification with fewer administered doses in responders and early transition to potentially more effective alternative treatments [second-line chemotherapy, poly (ADP-ribose) polymerase (PARP) inhibitors, or targeted alpha therapies] in non-responders, with similar PFS and OS to the published literature.^1,2,8

The response biomarkers utilised to inform patient care in this clinical programme included the PSA response at the first timepoint following the 6-dose ¹⁷⁷LuPSMA and a change in tumour volume or new lesions on the 6-week ¹⁷⁷Lu-SPECT/CT. Change in week-6 ¹⁷⁷Lu-SPECT tumour volume and rise in PSA at week 6 of ¹⁷⁷LuPSMA-I&T therapy have been previously shown to predict early PFS.⁴ Utilising these biomarkers allowed 35% of men (in RG 1) to have a significant treatment break, a median 6 months, with retreatment at first subsequent PSA rise. These men had durable PFS and OS outcomes. Such measures as treatment ‘holidays’ may potentially improve quality of life in men who often have treatment fatigue and side effects. Conversely, there is an opportunity cost in continuing an expensive treatment that is not controlling disease burden. Identifying patients with early disease progression using early response biomarkers may allow the opportunity for an alternative potentially effective treatment, such as cabazitaxel chemotherapy, PARP inhibitors, or targeted alpha therapies.^9–11

RECIP 1.0 is an interim biomarker proposal that utilises a 12-week ⁶⁸Ga-PSMA PET scan based on its predictive value for disease progression in a multi-centre ¹⁷⁷LuPSMA-617 therapy trial.¹² RECIP stratifies patients receiving ¹⁷⁷Lu PSMA therapy into PR, SD, or PD based on quantitative tumour volume. Similarly, the LUPIN study found that a week-12 quantitative ¹⁷⁷Lu-SPECT/CT predicted PSA-PFS in men being treated with ¹⁷⁷LuPSMA-617.^3,13 This study demonstrates that moving decision-making earlier to the 6-week timepoint of treatment using¹⁷⁷Lu-SPECT/CT + PSA progression is practical and maximises opportunities for personalising treatment response in individual patients. Furthermore, stratification of PR or disease progression on molecular imaging can potentially be made without requiring an additional PSMA-PET/CT procedure. This composite early response biomarker approach warrants further evaluation in prospective trials.

Generally, treatment response to systemic therapy in mCRPC has been monitored with PSA and radiographic PFS utilising diagnostic CT and bone scan.¹⁴ Like PSMA, PSA is a prostate cancer cell surface receptor, although PSA sheds into the bloodstream, allowing it to be measured in serum.¹⁵ Similar to PSMA, there is heterogeneity of PSA expression, meaning PSA may underestimate true disease volume in a proportion of men with mCRPC.¹⁶ RECIST radiographic progression is undertaken serially at a minimum 8-week intervals and is not a feasible early response biomarker tool. Utilising a combination of both early PSA response and early change on Lu-SPECT/CT provides a potentially stronger composite biomarker than either receptor response utilised in isolation.

Quantitative analysis of the ¹⁷⁷Lu-SPECT data demonstrated significant differences in Δ SUVmax and Δ SUVmean between RGs 1 and 3. The majority of patients receiving PSMA-targeted peptide receptor radionuclide therapy will get a drop in PSMA intensity, which is not predictive of OS.^12,17 However, these results suggest the depth of the reduction in SUVmax and SUVmean may be a proxy marker of radiation sensitivity and depth of cell death achieved. Currently, while we can measure PSMA characteristics at baseline to predict treatment response, we do not have an easy measure of radiation sensitivity, which is a significant factor in treatment resistance with ¹⁷⁷LuPSMA.^17,18 Treatment failure in RG 3 is likely due at least in part to a combination of both baseline PSMA heterogeneity/intensity and low radiation sensitivity. We can measure PSMA heterogeneity and expression at baseline (SUVmean), but the Δ Lu-SPECT parameters at 6 weeks may give some additional indication of radiation sensitivity, and this warrants further evaluation. Measures that address causes of treatment resistance (PARP inhibitors, targeted alpha therapies) may help improve responses in RG 3.^19–21

A higher proportion of men in RG 1 were chemotherapy naïve, potentially explaining the better treatment response rates in this group. However, these men were older, many considered not suitable for chemotherapy. The median age of men in RG 1 who had not undergone chemotherapy was 82. Older men with co-morbidities may particularly benefit from a ‘touch the earth lightly’ treatment paradigm with treatment breaks.²² Based on these results, ¹⁷⁷LuPSMA may be a substitute to chemotherapy in this patient group with many patients only requiring intermittent therapy to achieve disease control.

There are several significant limitations to this study. This is a not a prospective trial, but a retrospective analysis of a clinical programme. Hence, there are inherent biases in the study and the results can only thus be hypothesis generating. Some patients assigned to RG1 that were given a treatment holiday, elected not to have further treatment at PSA rise. This potentially led to a more limited duration of response in RG1 patients than may have been achieved. Furthermore, the definitions of visual disease response on ¹⁷⁷Lu-SPECT was not well defined, being classified as visually >30%. Despite this, the study raises important questions regarding the benefits of using composite imaging and biochemical response biomarkers to guide treatment and personalise ¹⁷⁷LuPSMA therapy responses. Further work is required in prospective trials to better define and standardise appropriate response thresholds for both ¹⁷⁷Lu-SPECT and early PSA in combination, and the role of image quantification. Randomised trials that address the value of early response biomarkers in ¹⁷⁷LuPSMA therapy would appear warranted based on preliminary results of this hypothesis generating data.

Conclusion

Footnotes

Acknowledgements

We would like to acknowledge the staff and patients from the Theranostics and Nuclear Medicine Department in St Vincent’s Hospital-Sydney.

Declarations

ORCID iD

Aron Poole

References

Hofman

Emmett

Sandhu

, et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021; 397: 797–804.

Sartor

de Bono

Chi

, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385: 1091–1103.

Pathmanandavel

Crumbaker

, et al. Evaluation of ¹⁷⁷Lu-PSMA SPECT quantitation as a response biomarker within a prospective ¹⁷⁷Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med 2023; 64: 221–226.

John

Pathmanandavel

Crumbaker

, et al. ¹⁷⁷Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression free survival for patients undergoing Lu PSMA I&T therapy. J Nucl Med. Epub ahead of print September 2022. DOI: 10.2967/jnumed.122.264677.

Niman

Buteau

Kruzer

, et al. Evaluation of a semi-automated whole body PET segmentation method applied to Diffuse Large B Cell Lymphoma. J Nucl Med 2018; 59: 592.

Scher

Morris

Stadler

, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016; 34: 1402–1418.

Eisenhauer

Therasse

Bogaerts

, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

Hofman

Violet

Hicks

, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825–833.

Yadav

Ballal

Sahoo

, et al. Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics 2020; 10: 9364–9377.

10.

de Bono

Oudard

Ozguroglu

, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154.

11.

de Bono

Mateo

Fizazi

, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020; 382: 2091–2102.

12.

Gafita

Rauscher

Weber

, et al. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 2022; 63: 1651–1658.

13.

Pathmanandavel

Crumbaker

Yam

, et al. ¹⁷⁷Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response of a Phase I/II trial. J Nucl Med 2022; 63: 560–566.

14.

Thana

Wood

. Followup imaging studies in metastatic castration-resistant prostate cancer: an individualized approach. Can Urol Assoc J 2019; 13: 201–202.

15.

Mikolajczyk

Marks

Partin

, et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797–802.

16.

Lee

Park

Kim

, et al. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol 2010; 51: 358–361.

17.

Pathmanandavel

Crumbaker

Nguyen

, et al. The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with ¹⁷⁷LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN). J Nucl Med 2023; 64: 69–74.

18.

Gafita

Calais

Grogan

, et al. Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 2021; 22: 1115–1125.

19.

Feuerecker

Tauber

Knorr

, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol 2021; 79: 343–350.

20.

Ruigrok

EAM

van Weerden

Nonnekens

, et al. The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research. Pharmaceutics 2019; 11: 560.

21.

Ruigrok

EAM

Verkaik

de Blois

, et al. Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment. Int J Mol Sci 2022; 23: 8037.

22.

Aapro

. Management of advanced prostate cancer in senior adults: the new landscape. Oncologist 2012; 17: 16–22.

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

Abstract

Background:

Objective:

Design:

Methods:

Results:

Conclusion:

Plain Language Summary

Keywords

Introduction

Materials and methods

Screening

Production

Imaging procedures and analysis

Visual imaging analysis

Quantitative imaging analysis

Study treatment

Statistical analyses

Results

Patient characteristics

Patient outcomes

Response group 1

Response group 2

Response group 3

Treatment following prior 177LuPSMA-617

Quantitative analysis of Lu-SPECT

Discussion

Conclusion

Footnotes

Acknowledgements

Declarations

ORCID iD

References

Treatment following prior ¹⁷⁷LuPSMA-617